Climb Bio Financials
This page shows Climb Bio (CLYM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Climb Bio’s dominant mechanic is an equity-funded development operation whose spending intensified while operating cash consumption widened in FY2025.
R&D investment increased from$14.3M in FY2024 to$46.7M in FY2025, showing that development spending—not broad cost retreat—remained central to operations. Meanwhile, the operating loss narrowed from$82.0M to$67.9M , so reported improvement coincided with a much heavier R&D mix rather than reduced scientific investment.
Cash conversion changed materially: FY2024 net loss was
The balance sheet is lightly debt-funded, with FY2025 liabilities of
Financial Health Signals
Climb Bio does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Climb Bio passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Climb Bio reported a net loss of $59.9M while operations used $54.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Climb Bio's EBITDA was -$67.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 17.4% from the prior year.
Climb Bio reported -$59.9M in net income in fiscal year 2025. This represents an increase of 19.0% from the prior year.
Climb Bio earned -$0.88 per diluted share (EPS) in fiscal year 2025. This represents an increase of 42.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Climb Bio recorded an outflow of $54.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 250.5% from the prior year.
Climb Bio held $35.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Climb Bio's ROE was -37.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Climb Bio invested $46.7M in research and development in fiscal year 2025. This represents an increase of 225.8% from the prior year.
Climb Bio invested $186K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
CLYM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $9.7M+3.6% | $9.4M | N/A | $9.1M+38.0% | $6.6M-62.1% | $17.3M | N/A | $6.2M |
| SG&A Expenses | $5.6M-3.3% | $5.8M | N/A | $5.8M+41.9% | $4.1M-27.9% | $5.7M | N/A | $5.5M |
| Operating Income | -$15.4M-1.0% | -$15.2M | N/A | -$14.9M-39.5% | -$10.7M+53.6% | -$23.0M | N/A | -$11.7M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | $0 | N/A | $0 |
| Net Income | -$13.5M+1.6% | -$13.7M | N/A | -$12.9M-48.7% | -$8.7M+58.3% | -$20.8M | N/A | -$8.9M |
| EPS (Diluted) | -$0.18+10.0% | -$0.20+20.0% | -$0.25-31.6% | -$0.19-46.2% | -$0.13+58.1% | -$0.31-875.0% | $0.04+130.8% | -$0.13 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
CLYM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $246.3M+61.6% | $152.4M-9.2% | $167.7M-8.0% | $182.3M-5.2% | $192.4M-4.2% | $200.7M-7.6% | $217.2M-2.3% | $222.2M |
| Current Assets | $186.6M+64.6% | $113.4M+7.1% | $105.8M+16.4% | $91.0M+4.1% | $87.4M-12.9% | $100.3M-35.2% | $154.9M-21.6% | $197.6M |
| Cash & Equivalents | $44.1M+427.8% | $8.4M-76.6% | $35.7M+38.3% | $25.8M+13.8% | $22.7M-21.8% | $29.0M-66.7% | $87.2M-40.3% | $146.2M |
| Total Liabilities | $6.7M+57.4% | $4.3M-41.0% | $7.3M+37.1% | $5.3M-19.9% | $6.6M-10.0% | $7.4M+38.6% | $5.3M+55.0% | $3.4M |
| Current Liabilities | $5.9M+45.8% | $4.1M-41.7% | $7.0M+41.1% | $4.9M-20.2% | $6.2M-11.8% | $7.0M+42.7% | $4.9M+44.1% | $3.4M |
| Total Equity | $239.5M+61.8% | $148.1M-7.7% | $160.5M-9.3% | $177.0M-4.7% | $185.8M-3.9% | $193.4M-8.7% | $211.9M-3.2% | $218.8M |
| Retained Earnings | -$316.9M-4.4% | -$303.4M-4.7% | -$289.7M-6.4% | -$272.2M-5.0% | -$259.3M-3.5% | -$250.7M-9.0% | -$229.9M-3.8% | -$221.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CLYM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.5M+26.7% | -$14.4M+8.0% | -$15.6M-28.8% | -$12.1M-8.9% | -$11.1M+27.8% | -$15.4M-179.6% | -$5.5M+26.9% | -$7.6M |
| Capital Expenditures | N/A | N/A | $0-100.0% | $109K | N/A | N/A | $0 | $0 |
| Free Cash Flow | N/A | N/A | -$15.6M-27.7% | -$12.2M | N/A | N/A | -$5.5M+26.9% | -$7.6M |
| Investing Cash Flow | -$57.3M-342.0% | -$13.0M-150.7% | $25.5M+67.4% | $15.3M+218.8% | $4.8M+111.2% | -$42.8M+20.0% | -$53.4M+25.6% | -$71.8M |
| Financing Cash Flow | $103.7M+2073960.0% | $5K+123.8% | -$21K | $0 | $0 | $0-100.0% | $41K-98.2% | $2.3M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CLYM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -5.6%+3.6pp | -9.3% | N/A | -7.3%-2.6pp | -4.7%+6.1pp | -10.8% | N/A | -4.1% |
| Return on Assets | -5.5%+3.5pp | -9.0% | N/A | -7.1%-2.6pp | -4.5%+5.8pp | -10.3% | N/A | -4.0% |
| Current Ratio | 31.45+3.6x | 27.86+12.7x | 15.16-3.2x | 18.38+4.3x | 14.08-0.2x | 14.25-17.2x | 31.41-26.3x | 57.73 |
| Debt-to-Equity | 0.030.0x | 0.030.0x | 0.050.0x | 0.030.0x | 0.040.0x | 0.040.0x | 0.030.0x | 0.02 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Climb Bio Ranks
Frequently Asked Questions
Is Climb Bio profitable?
No, Climb Bio (CLYM) reported a net income of -$59.9M in fiscal year 2025.
What is Climb Bio's EBITDA?
Climb Bio (CLYM) had EBITDA of -$67.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Climb Bio's return on equity (ROE)?
Climb Bio (CLYM) has a return on equity of -37.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Climb Bio's free cash flow?
Climb Bio (CLYM) recorded an outflow of $54.5M in free cash flow during fiscal year 2025. This represents a -250.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Climb Bio's operating cash flow?
Climb Bio (CLYM) recorded an outflow of $54.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Climb Bio's total assets?
Climb Bio (CLYM) had $167.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Climb Bio's capital expenditures?
Climb Bio (CLYM) invested $186K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Climb Bio spend on research and development?
Climb Bio (CLYM) invested $46.7M in research and development during fiscal year 2025.
What is Climb Bio's current ratio?
Climb Bio (CLYM) had a current ratio of 15.16 as of fiscal year 2025, which is generally considered healthy.
What is Climb Bio's debt-to-equity ratio?
Climb Bio (CLYM) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Climb Bio's return on assets (ROA)?
Climb Bio (CLYM) had a return on assets of -35.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Climb Bio's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Climb Bio (CLYM) held $160.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $54.4M over that year. Dividing the one by the other, the reported balance equals about 35 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Climb Bio's Piotroski F-Score?
Climb Bio (CLYM) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Climb Bio's earnings high quality?
Climb Bio (CLYM) reported a net loss of $59.9M while operations used $54.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.